Table 1. Baseline characteristics of individuals who had received a first or second dose of BNT162b2 or CoronaVac from 23 February to 9 September 2021 in Hong Kong SAR, China.
| Baseline characteristic | First dose recipients | Second dose recipients | ||||||
|---|---|---|---|---|---|---|---|---|
| Before weighting | After weighting | Before weighting | After weighting | |||||
| Mean ± SD or N (%) | SMD | SMD | Mean ± SD or N (%) | SMD | SMD | |||
| BNT162b2 (N = 1,308,820) |
CoronaVac (N = 955,859) |
BNT162b2 (N = 1,116,677) |
CoronaVac (N = 821,560) |
|||||
| Age, years | 45.7 ± 16.0 | 55.3 ± 14.1 | 0.63 | 0.02 | 45.9 ± 15.7 | 54.8 ± 13.9 | 0.59 | 0.02 |
| Sex | 0.03 | 0.00 | 0.03 | 0.00 | ||||
| Male | 584,158 (44.6%) | 439,928 (46.0%) | 502,740 (45.0%) | 383,164 (46.6%) | ||||
| Female | 724,662 (55.4%) | 515,931 (54.0%) | 613,937 (55.0%) | 438,396 (53.4%) | ||||
| Dosing interval, days | NA | NA | NA | NA | 22.8 ± 4.3 | 29.2 ± 5.2 | NA | NA |
| Venue for vaccination | NA | NA | NA | NA | ||||
| Community vaccination center | 1,264,703 (98.5%) | 463,815 (50.3%) | 1,099,211 (98.4%) | 428,794 (52.2%) | ||||
| Clinic | 0 (0.0%) | 441,526 (47.9%) | 0 (0.0%) | 378,865 (46.1%) | ||||
| Other | 19,249 (1.5%) | 17,198 (1.9%) | 17,377 (1.6%) | 13,497 (1.6%) | ||||
| Previous SARS-CoV-2 infectiona | 4,642 (0.4%) | 1,690 (0.2%) | 0.03 | 0.00 | 422 (0.0%) | 263 (0.0%) | 0.00 | 0.00 |
| Pre-existing comorbidities | ||||||||
| Charlson Comorbidity Index | 1.4 ± 1.5 | 2.2 ± 1.5 | 0.56 | 0.01 | 1.4 ± 1.5 | 2.1 ± 1.5 | 0.52 | 0.01 |
| History of AESI | 395,232 (30.2%) | 382,549 (40.0%) | 0.21 | 0.02 | 340,006 (30.4%) | 323,326 (39.4%) | 0.19 | 0.01 |
| Myocardial infarction | 1,662 (0.1%) | 2,238 (0.2%) | 0.03 | 0.00 | 1,347 (0.1%) | 1,688 (0.2%) | 0.02 | 0.00 |
| Peripheral vascular disease | 657 (0.1%) | 881 (0.1%) | 0.02 | 0.00 | 513 (0.0%) | 653 (0.1%) | 0.01 | 0.00 |
| Cerebrovascular disease | 11,591 (0.9%) | 17,638 (1.8%) | 0.08 | 0.00 | 9,374 (0.8%) | 13,259 (1.6%) | 0.07 | 0.00 |
| Coronary artery disease | 253,883 (19.4%) | 343,413 (35.9%) | 0.00 | 0.00 | 210,140 (18.8%) | 274,353 (33.4%) | 0.00 | 0.00 |
| Chronic obstructive pulmonary disease | 11,837 (0.9%) | 11,324 (1.2%) | 0.03 | 0.00 | 9,817 (0.9%) | 8,954 (1.1%) | 0.02 | 0.00 |
| Dementia | 251 (0.0%) | 607 (0.1%) | 0.02 | 0.00 | 203 (0.0%) | 261 (0.0%) | 0.01 | 0.00 |
| Paralysis | 321 (0.0%) | 525 (0.1%) | 0.02 | 0.00 | 252 (0.0%) | 359 (0.0%) | 0.01 | 0.00 |
| Diabetes without chronic complication | 75,440 (5.8%) | 98,194 (10.3%) | 0.17 | 0.00 | 62,113 (5.6%) | 77,702 (9.5%) | 0.15 | 0.00 |
| Diabetes with chronic complication | 2,366 (0.2%) | 3,135 (0.3%) | 0.03 | 0.00 | 1,832 (0.2%) | 2,350 (0.3%) | 0.03 | 0.00 |
| Hypertension | 177,913 (13.6%) | 225,107 (23.6%) | 0.08 | 0.00 | 148,978 (13.3%) | 182,379 (22.2%) | 0.07 | 0.00 |
| Chronic renal failure | 3,498 (0.3%) | 4,901 (0.5%) | 0.04 | 0.00 | 2,720 (0.2%) | 3,708 (0.5%) | 0.04 | 0.00 |
| Mild liver disease | 631 (0.0%) | 708 (0.1%) | 0.01 | 0.00 | 502 (0.0%) | 568 (0.1%) | 0.01 | 0.00 |
| Moderate-severe liver disease | 380 (0.0%) | 426 (0.0%) | 0.01 | 0.00 | 305 (0.0%) | 326 (0.0%) | 0.01 | 0.00 |
| Ulcers | 4,585 (0.4%) | 6,086 (0.6%) | 0.04 | 0.00 | 3,779 (0.3%) | 4,953 (0.6%) | 0.04 | 0.00 |
| Rheumatoid arthritis or other inflammatory polyarthropathy | 2,514 (0.2%) | 2,061 (0.2%) | 0.01 | 0.00 | 1,997 (0.2%) | 1,647 (0.2%) | 0.00 | 0.00 |
| Malignancy | 12,695 (1.0%) | 12,068 (1.3%) | 0.03 | 0.00 | 10,253 (0.9%) | 9,386 (1.1%) | 0.02 | 0.00 |
| Metastatic solid tumor | 1,094 (0.1%) | 1,108 (0.1%) | 0.01 | 0.00 | 840 (0.1%) | 802 (0.1%) | 0.01 | 0.00 |
| Medication use in the past 90 days | ||||||||
| Renin–angiotensin system agent | 82,760 (6.3%) | 101,285 (10.6%) | 0.15 | 0.00 | 66,641 (6.0%) | 78,660 (9.6%) | 0.14 | 0.00 |
| Beta blocker | 46,915 (3.6%) | 57,279 (6.0%) | 0.11 | 0.00 | 37,359 (3.3%) | 43,334 (5.3%) | 0.10 | 0.00 |
| Calcium channel blocker | 124,214 (9.5%) | 158,884 (16.6%) | 0.21 | 0.00 | 101,220 (9.1%) | 125,113 (15.2%) | 0.19 | 0.00 |
| Diuretic | 11,455 (0.9%) | 14,847 (1.6%) | 0.06 | 0.00 | 8,929 (0.8%) | 10,863 (1.3%) | 0.05 | 0.00 |
| Nitrate | 7,081 (0.5%) | 9,705 (1.0%) | 0.05 | 0.00 | 5,550 (0.5%) | 7,200 (0.9%) | 0.05 | 0.00 |
| Lipid-lowering agent | 119,105 (9.1%) | 146,738 (15.4%) | 0.19 | 0.00 | 96,959 (8.7%) | 114,869 (14.0%) | 0.17 | 0.00 |
| Insulin | 7,284 (0.6%) | 8,406 (0.9%) | 0.04 | 0.00 | 5,527 (0.5%) | 6,031 (0.7%) | 0.03 | 0.00 |
| Antidiabetic drug | 63,170 (4.8%) | 80,903 (8.5%) | 0.15 | 0.00 | 50,403 (4.5%) | 62,001 (7.5%) | 0.13 | 0.00 |
| Antiarrhythmic drug | 579 (0.0%) | 599 (0.1%) | 0.01 | 0.00 | 445 (0.0%) | 421 (0.1%) | 0.01 | 0.00 |
| Cardiac glycoside | 739 (0.1%) | 1,049 (0.1%) | 0.02 | 0.00 | 560 (0.1%) | 689 (0.1%) | 0.01 | 0.00 |
| Oral anticoagulant | 2,924 (0.2%) | 4,028 (0.4%) | 0.03 | 0.00 | 2,167 (0.2%) | 2,772 (0.3%) | 0.03 | 0.00 |
| Parenteral anticoagulant | 396 (0.0%) | 340 (0.0%) | 0.00 | 0.00 | 261 (0.0%) | 215 (0.0%) | 0.00 | 0.00 |
| Antiplatelet | 32,943 (2.5%) | 43,862 (4.6%) | 0.11 | 0.00 | 26,140 (2.3%) | 32,890 (4.0%) | 0.09 | 0.00 |
| Antifibrinolytic or hemostatic | 4,946 (0.4%) | 3,540 (0.4%) | 0.00 | 0.00 | 4,116 (0.4%) | 2,912 (0.4%) | 0.00 | 0.00 |
| Hormonal agent (contraceptive, HRT, SERM) | 6,485 (0.5%) | 4,039 (0.4%) | 0.01 | 0.00 | 5,202 (0.5%) | 3,045 (0.4%) | 0.01 | 0.00 |
| Glucocorticoid | 6,252 (0.5%) | 4,790 (0.5%) | 0.00 | 0.00 | 4,784 (0.4%) | 3,637 (0.4%) | 0.00 | 0.00 |
| Antidepressant | 31,259 (2.4%) | 26,354 (2.8%) | 0.02 | 0.00 | 25,771 (2.3%) | 21,280 (2.6%) | 0.02 | 0.00 |
| Bevacizumab | 32 (0.0%) | 23 (0.0%) | 0.00 | 0.00 | 24 (0.0%) | 13 (0.0%) | 0.00 | 0.00 |
| Tranexamic acid | 4,921 (0.4%) | 3,526 (0.4%) | 0.00 | 0.00 | 4,093 (0.4%) | 2,905 (0.4%) | 0.00 | 0.00 |
| Intravenous immunoglobulin | 47 (0.0%) | 28 (0.0%) | 0.00 | 0.00 | 33 (0.0%) | 15 (0.0%) | 0.00 | 0.00 |
| NSAID | 72,371 (5.5%) | 54,715 (5.7%) | 0.01 | 0.00 | 62,948 (5.6%) | 46,969 (5.7%) | 0.00 | 0.00 |
| Drug for gout | 11,084 (0.8%) | 12,782 (1.3%) | 0.05 | 0.00 | 9,167 (0.8%) | 10,295 (1.3%) | 0.04 | 0.00 |
| Antiepileptic drug | 12,728 (1.0%) | 10,132 (1.1%) | 0.01 | 0.00 | 10,171 (0.9%) | 7,498 (0.9%) | 0.00 | 0.00 |
| Drug for control of epilepsy | 12,722 (1.0%) | 10,125 (1.1%) | 0.01 | 0.00 | 10,163 (0.9%) | 7,493 (0.9%) | 0.00 | 0.00 |
| Antiviral drug | 8,342 (0.6%) | 8,192 (0.9%) | 0.03 | 0.00 | 6,845 (0.6%) | 6,587 (0.8%) | 0.02 | 0.00 |
| Antibacterial drug | 38,297 (2.9%) | 28,903 (3.0%) | 0.01 | 0.00 | 31,342 (2.8%) | 23,029 (2.8%) | 0.00 | 0.00 |
| Immunosuppressant | 3,634 (0.3%) | 2,336 (0.2%) | 0.01 | 0.00 | 2,701 (0.2%) | 1,772 (0.2%) | 0.01 | 0.00 |
| Adrenaline | 91 (0.0%) | 132 (0.0%) | 0.01 | 0.00 | 60 (0.0%) | 77 (0.0%) | 0.00 | 0.00 |
| Oral contraceptive | 1,162 (0.1%) | 388 (0.0%) | 0.02 | 0.00 | 943 (0.1%) | 320 (0.0%) | 0.02 | 0.00 |
| HRT | 2,947 (0.2%) | 1,711 (0.2%) | 0.01 | 0.00 | 2,407 (0.2%) | 1,374 (0.2%) | 0.01 | 0.00 |
| Hormonal agent in malignant disease | 2,463 (0.2%) | 1,960 (0.2%) | 0.00 | 0.00 | 1,912 (0.2%) | 1,372 (0.2%) | 0.00 | 0.00 |
AESI, adverse event of special interest; HRT, hormone replacement therapy; NSAID, non-steroidal anti-inflammatory drug; SD, standard deviation; SERM, selective estrogen receptor modulator; SMD, standardized mean difference.
aPrevious SARS-CoV-2 infection was defined as ever having a positive result on the SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) test before COVID-19 vaccination.